Gram-negative (GN) bacterial infections present a daunting challenge for clinicians, as they can be especially hard to treat and are associated with high morbidity and mortality, particularly when dealing with carbapenem-resistant Enterobacteriaceae (CRE) and other antibiotic-resistant pathogens. While the development of novel antibiotic classes to overcome resistance has been lacking, recent advances in the development of next-generation agents as of well-established classes has the potential to help address the critical need for effective therapies for serious, drug-resistant GN infections. As such, it is crucial for members of the infectious disease clinical team who treat these patients to understand how these emerging therapies differ from their more conventional predecessors, how they may effectively fit into current treatment paradigms, and how to effectively approach dosing and therapeutic drug management in order to optimize health outcomes for these difficult-to-treat patients.
Elsevier CME is committed to providing the topics necessary to stay up-to-date in the field of infectious diseases.
This CME/CE-accredited CME Snapshot™ four-part series is intended for infectious disease physicians and other clinicians who manage patients with HIV. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with HIV.